S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Withdrawn before enrolling · Phase 2
Conditions studied: Multiple Myeloma, Plasma Cell Myeloma
In brief
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide and lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, cisplatin, doxorubicin hydrochloride, cyclophosphamide, etoposide, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combining chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving bortezomib, thalidomide, and combination chemotherapy before and after transplant and lenalidomide after transplant may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying how well giving bortezomib, thalidomide, and lenalidomide together with combination chemotherapy and autologous stem cell transplant works in treating patients with newly diagnosed multiple myeloma.
Key facts
- Study ID
- NCT01055301
- Run by
- SWOG Cancer Research Network
- People needed
- 0
- Starts
- 2011-07-01
- Expected to finish
- 2011-07-01
- Last updated by the study team
- 2015-03-06
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Tulane Cancer Center Office of Clinical Research — Alexandria, Louisiana, United States
- Hematology-Oncology Clinic — Baton Rouge, Louisiana, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- University of Mississippi Cancer Clinic — Jackson, Mississippi, United States
- Island Hospital Cancer Care Center at Island Hospital — Anacortes, Washington, United States
- St. Joseph Cancer Center — Bellingham, Washington, United States
- Olympic Hematology and Oncology — Bremerton, Washington, United States
- Highline Medical Center Cancer Center — Burien, Washington, United States
- Columbia Basin Hematology — Kennewick, Washington, United States
- Skagit Valley Hospital Cancer Care Center — Mount Vernon, Washington, United States
- Harrison Poulsbo Hematology and Onocology — Poulsbo, Washington, United States
- Harborview Medical Center — Seattle, Washington, United States
- Minor and James Medical, PLLC — Seattle, Washington, United States
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
- Group Health Central Hospital — Seattle, Washington, United States
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus — Seattle, Washington, United States
- University Cancer Center at University of Washington Medical Center — Seattle, Washington, United States
- North Puget Oncology at United General Hospital — Sedro-Woolley, Washington, United States
- Cancer Care Northwest - Spokane South — Spokane, Washington, United States
- Evergreen Hematology and Oncology, PS — Spokane, Washington, United States
- Wenatchee Valley Medical Center — Wenatchee, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.